Ozempic vs Mounjaro: How Semaglutide and Tirzepatide Compare on Weight Loss and Side Effects

You have been managing your weight carefully for months. You brought your Ozempic pen from home, kept it refrigerated in your villa in Bang Tao, and now you are two weeks into your Phuket stay wondering whether Mounjaro would have been the better choice. Or maybe you have heard about both and want to start one while you are here, and you need a doctor who can talk you through it in English.

The short answer: Mounjaro produces more weight loss on average, but both medications work, both have side effects, and the right choice depends on your health history. What follows gives you the clinical picture clearly, so that when you sit down with a doctor, you are asking the right questions.

How Each Drug Works

Ozempic contains semaglutide. It mimics a gut hormone called GLP-1, which tells your brain you are full, slows how fast food leaves your stomach, and prompts insulin release when blood sugar rises.

Mounjaro contains tirzepatide, which activates both GLP-1 receptors and GIP receptors. GIP is a second gut hormone that works alongside GLP-1. Acting on both pathways at once produces stronger appetite suppression and greater fat loss than targeting GLP-1 alone. That dual action is the core reason Mounjaro tends to outperform Ozempic on weight outcomes.

Both are weekly injections given with a pre-filled pen, self-administered under the skin, usually in the abdomen, thigh, or upper arm.

What the Weight Loss Evidence Actually Shows

The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in people with obesity. Tirzepatide produced significantly greater weight loss. A 2024 observational study in JAMA Network Open found tirzepatide users lost roughly twice the body weight percentage compared to semaglutide users over the same period, though that study used lower semaglutide doses than are now standard for weight management.

At comparable doses, tirzepatide still comes out ahead, but the gap may be smaller than early headlines suggested. Individual response varies considerably. Some patients do very well on semaglutide. Some plateau on tirzepatide. There is no guaranteed outcome with either drug.

Your starting weight, other health conditions, and how your body tolerates dose increases all affect the result.

Approved Uses and Prescribing Context

Ozempic is approved for type 2 diabetes management. Wegovy, the higher-dose version of the same drug, carries the formal weight loss approval. In practice, semaglutide is often prescribed off-label for weight management at Ozempic doses when Wegovy is unavailable. This is legal and common, but it requires a physician who understands the distinction and can document it properly.

Mounjaro is approved for type 2 diabetes. Zepbound, the weight-loss-approved version of tirzepatide, carries the obesity indication. The same off-label pattern applies in markets where Zepbound is not yet consistently available, including parts of Southeast Asia.

In Thailand, both semaglutide and tirzepatide products are prescription-only under Thai FDA regulations. You cannot purchase either legally over the counter.

Side Effects and When to See a Doctor

Both medications cause similar GI side effects: nausea, vomiting, diarrhea, constipation, and reduced appetite. These are most pronounced during dose titration, the period where your dose is gradually increased over weeks to months. They usually ease as your body adjusts. Slowing the dose increase schedule helps considerably.

Less common but serious risks include pancreatitis. If you develop severe or persistent upper abdominal pain that radiates to your back, stop the injection and get medical care the same day. Both drugs carry a warning about a rare risk of thyroid tumors seen in animal studies. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use either medication.

Ozempic also carries an FDA cardiovascular benefit indication for patients with type 2 diabetes and established heart disease, based on the SUSTAIN-6 trial. Tirzepatide’s cardiovascular outcomes trial, SURPASS-CVOT, published results in 2025. It showed tirzepatide was non-inferior to dulaglutide for major cardiovascular events in people with type 2 diabetes and atherosclerotic disease, but the trial compared two active drugs rather than placebo, so direct comparison with Ozempic’s placebo-controlled data is not straightforward.

If you are in Phuket and experiencing persistent vomiting, signs of dehydration, or severe abdominal pain while on either medication, walk into Takecare Clinic Phuket in Patong. No appointment is needed. The doctor will need to know your medication, current dose, and when symptoms started.

Getting Ozempic or Mounjaro in Phuket

Both drugs require a prescription from a licensed physician in Thailand. A consultation is not optional. Buying these medications from an unverified source carries real risk: counterfeit GLP-1 products exist in the region.

Stock availability in Phuket varies. Semaglutide products have been more consistently available than tirzepatide in many Thai pharmacies, though this changes. If you need a prescription, a refill, or a medical review before continuing, an English-speaking doctor in Phuket at Takecare Clinic can assess you without an appointment.

If you are already on one of these medications and need a prescription refill in Phuket, bring your current pen, packaging, and any records from your home physician. That makes the consultation faster and the prescribing safer.

Travelling with GLP-1 Medications: Storage and Missed Doses

Both pens must be stored refrigerated between 2 and 8 degrees Celsius before first use. Once in use, Ozempic pens can be kept at room temperature below 30 degrees Celsius for up to 56 days according to the product label. For Mounjaro, the in-use room-temperature allowance varies by pen format and market: the KwikPen is labeled for up to 30 days, while the US single-dose pen is labeled for up to 21 days. Check the label of your specific pen for the exact figure. Phuket’s heat matters here. A pen left in a hot car or in direct sun is likely compromised. Keep it in the hotel minibar if you cannot access a fridge.

A missed dose is less critical than many patients think. If you miss your weekly injection by a few days and your next scheduled dose is still more than two days away, take it and return to your usual schedule. If your next dose is within two days, skip the missed one and continue normally. Do not double up. If you are unsure, a doctor at Takecare Clinic can advise by walk-in or telemedicine consultation in Phuket.

Switching Between Ozempic and Mounjaro

Patients do move from semaglutide to tirzepatide, and some go the other direction. There is no required washout period between the two. However, when switching to tirzepatide, most physicians will restart at the lowest available dose, currently 2.5 mg weekly, regardless of the semaglutide dose you were on. This reduces the risk of compounding GI side effects during the transition.

Switching to a higher-efficacy medication mid-plateau is reasonable. It requires a doctor who knows your current dose, your weight history, and any side effects you have had. Do not self-switch based on what you read online.

Weight loss percentages are from approved-indication trials (STEP and SURMOUNT series). Results in clinical practice vary.